150 related articles for article (PubMed ID: 37995465)
1. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
[TBL] [Abstract][Full Text] [Related]
2. [Increase of CXCL10 serum level in systemic sclerosis interstitial pneumonia].
Tiev KP; Chatenoud L; Kettaneh A; Tolédano C; Bach JF; Cabane J
Rev Med Interne; 2009 Nov; 30(11):942-6. PubMed ID: 19577826
[TBL] [Abstract][Full Text] [Related]
3. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
[TBL] [Abstract][Full Text] [Related]
4. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
5. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
6. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
7. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis.
Meloni F; Caporali R; Marone Bianco A; Paschetto E; Morosini M; Fietta AM; Patrizio V; Bobbio-Pallavicini F; Pozzi E; Montecucco C
Sarcoidosis Vasc Diffuse Lung Dis; 2004 Jun; 21(2):111-8. PubMed ID: 15281432
[TBL] [Abstract][Full Text] [Related]
8. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
[TBL] [Abstract][Full Text] [Related]
9. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
Kowal-Bielecka O; Kowal K; Highland KB; Silver RM
Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959
[TBL] [Abstract][Full Text] [Related]
10. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.
Assassi S; Li N; Volkmann ER; Mayes MD; Rünger D; Ying J; Roth MD; Hinchcliff M; Khanna D; Frech T; Clements PJ; Furst DE; Goldin J; Bernstein EJ; Castelino FV; Domsic RT; Gordon JK; Hant FN; Shah AA; Shanmugam VK; Steen VD; Elashoff RM; Tashkin DP
Arthritis Rheumatol; 2021 Jun; 73(6):1005-1013. PubMed ID: 33350170
[TBL] [Abstract][Full Text] [Related]
11. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features.
Kameda M; Otsuka M; Chiba H; Kuronuma K; Hasegawa T; Takahashi H; Takahashi H
PLoS One; 2020; 15(11):e0241719. PubMed ID: 33137121
[TBL] [Abstract][Full Text] [Related]
12. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
[TBL] [Abstract][Full Text] [Related]
13. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G
Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
[TBL] [Abstract][Full Text] [Related]
15. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
[TBL] [Abstract][Full Text] [Related]
18. Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis.
Becker MO; Radic M; Schmidt K; Huscher D; Riedlinger A; Michelfelder M; Meisel C; Ewert R; Burmester GR; Riemekasten G
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(4):274-284. PubMed ID: 32476963
[TBL] [Abstract][Full Text] [Related]
19. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
20. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
